MEASURE CLEARANCE OF REPLICATION-COMPETENT HIV-1 IN RESTING MEMORY CD4+ CELLS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies have shown that HIV can survive in cells for long periods of time even while a person is on HIV therapy. The HIV virus can survive in these cells for a very long time in a "resting" or "latent" state. The virus in these cells is not active but could become active in the future. The main purpose of this research study is to count the number of cells with HIV that are resting, or latent, in the blood of people taking a new combination of HIV drugs. The latent reservoir test has not been proven to be of clinical benefit. The combination of HIV drugs includes an investigational HIV drug called T-20 (enfuvirtide, or Fuzeon), which is not approved by the U. S. Food and Drug Administration (FDA). This study will look at the safety of T-20 when it is given with four FDA-approved HIV drugs. These other drugs are tenofovir (TDF, or Viread), lamivudine (3TC, or Epivir), saquinavir (SQV, or Invirase), and ritonavir (RTV, or Norvir). The dosage (dose and schedule) of ritonavir and saquinavir in this study were chosen based on experience in the treatment of people with HIV, but are different than the FDA-approved dosages.